Fear and anxiety disorders affect a significant proportion of the dog population, causing chronic psychological welfare compromise that frequently goes unrecognised. Understanding the spectrum of anxiety-related conditions enables more effective management.
Studies suggest 70-80% of dogs exhibit at least one fear or anxiety-related behaviour that owners consider problematic. Fear of strangers, fear of other dogs, noise phobia, and generalised anxiety are particularly common. However, many dogs with anxiety disorders have owners who do not recognise the signs—interpreting anxious behaviour as "stubborn," "disobedient," or "dramatic" rather than as expressions of genuine psychological distress. Improving owner recognition is a major welfare intervention opportunity.
Fear is an adaptive response to a present threat; anxiety is apprehension about anticipated threat. Both involve similar physiological activation but require different treatment approaches. Fearful dogs respond to specific triggers; anxious dogs maintain elevated arousal even without apparent triggers. The distinction guides both pharmacological and behavioural treatment—generalised anxiety disorder often requires daily anti-anxiety medication, while specific phobias may be managed situationally.
Chronic anxiety causes chronic hypothalamic-pituitary-adrenal (HPA) axis activation, with elevated cortisol causing immune suppression, gastrointestinal dysfunction, cardiovascular changes, and potentially shortened lifespan. Anxious dogs show altered gut microbiome composition, increased inflammatory markers, and reduced immune competence. The welfare cost extends beyond behavioural signs to genuine physiological damage from chronic stress.
Systematic desensitisation (gradual, controlled exposure to trigger stimuli at sub-fear-threshold levels) combined with counter-conditioning (building positive associations with previously feared stimuli) is evidence-based treatment for specific fears. The process must maintain sub-threshold exposure—any exposure causing fear responses reinforces the fear rather than treating it. Patience, professional guidance, and realistic timescales (weeks to months) are essential for owner commitment.
Daily anxiolytic medication (SSRIs: fluoxetine, sertraline; TCAs: clomipramine) provides the physiological foundation for behaviour modification in moderate-to-severe anxiety disorders. These medications reduce baseline arousal, enabling dogs to engage with desensitisation programmes they otherwise cannot access. Situational medications (trazodone, alprazolam, imepitoin) manage high-arousal predictable events. Medication without behaviour modification provides only partial benefit; combined approaches produce superior welfare outcomes.